Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Regulation of different inflammatory diseases by impacting the mevalonate pathway IMMUNOLOGY Zeiser, R., Maas, K., Youssef, S., Duerr, C., Steinman, L., Negrin, R. S. 2009; 127 (1): 18-25

Abstract

The 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) interfere with the mevalonate pathway. While initially developed for their lipid-lowering properties, statins have been extensively investigated with respect to their impact on autoantigen and alloantigen driven immune responses. Mechanistically it was shown that statins modify immune responses on several levels, including effects on dendritic cells, endothelial cells, macrophages, B cells and T cells. Several lines of evidence suggest that statins act in a disease-specific manner and are not effective in each immune disorder. This review discusses possible modes of action of statins in modulating immunity towards autoantigens and alloantigens.

View details for DOI 10.1111/j.1365-2567.2008.03011.x

View details for Web of Science ID 000264784600003

View details for PubMedID 19191903

View details for PubMedCentralID PMC2678178